@article{mbs:/content/journal/jmm/10.1099/jmm.0.47853-0, author = "Capoor, Malini R. and Nair, Deepthi and Posti, Jitendra and Singhal, Smita and Deb, Monorama and Aggarwal, Pushpa and Pillai, Parukutty", title = "Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.", journal= "Journal of Medical Microbiology", year = "2009", volume = "58", number = "3", pages = "337-341", doi = "https://doi.org/10.1099/jmm.0.47853-0", url = "https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.47853-0", publisher = "Microbiology Society", issn = "1473-5644", type = "Journal Article", keywords = "FDA, Food and Drug Administration", keywords = "EUCAST, European committee on antimicrobial susceptibility testing", keywords = "ESBL, extended-spectrum β-lactamase", keywords = "NAR, nalidixic acid-resistant", keywords = "CLSI, Clinical and Laboratory Standards Institute", keywords = "MDR, multidrug-resistant", keywords = "MIC50 and MIC90, antimicrobial concentration that inhibited growth of 50 and 90 %, respectively, of the strains", abstract = "Antimicrobial resistance in Salmonella spp. is of grave concern, more so in quinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing isolates that cause complicated infections. The MIC of azithromycin, ciprofloxacin, cefixime, cefepime, ceftriaxone, gatifloxacin, imipenem, levofloxacin, meropenem and ofloxacin (E-test strip) and tigecycline and faropenem (agar dilution) against 210 Salmonella spp. was determined. MIC90 (defined as the antimicrobial concentration thatinhibited growth of 90 % of the strains) of the carbapenems (imipenem and meropenem) for Salmonella Typhi and Salmonella Paratyphi A was 0.064 μg ml−1. MIC90 of faropenem was 0.25 μg ml−1 for S. Typhi, S. Paratyphi A and Salmonella Typhimurium. The MIC90 of azithromycin for all Salmonella spp. ranged from 8 to 16 μg ml−1. Tigecycline showed an MIC90 of 2 μg ml−1 for S. Typhi, 1 μg ml−1 for S. Paratyphi A and 4 μg ml−1 for S. Typhimurium. We concluded that tigecycline and the carbapenems are likely to have roles in the final stage of treatment of quinolone-resistant and ESBL-producing multidrug-resistant salmonellae.", }